Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML
Steffan T. Nawrocki(University of Arizona), Jennifer S. Carew(University of Arizona), Steve Wong, Hetty E. Carraway(Cleveland Clinic), Valeria Visconte(Cleveland Clinic), Bartlomiej Przychodzen(Cleveland Clinic), Stevan Djakovic, Ronan Le Moigne, Mikkael A. Sekeres(University of Miami), Mark Rolfe(Unknown), Daniel J. Anderson, Yingchun Han(Shenyang Agricultural University), Anjali S. Advani(Cleveland Clinic), Han-Jie Zhou, David J. Wustrow(Rapt Therapeutics (United States)), Jaroslaw P. Maciejewski(Cleveland Clinic), Kevin R. Kelly(Keck Hospital of USC)
Cited by 1
Related Papers
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
|Science|1995|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k